Clinical trials: Cetuximab
Advanced Colorectal Carcinoma, Immunotherapy
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
Study Title: A Prospective, Randomized, Phase II, Multicenter Clinical Study of Serplulimab Combined with Targeted Therapy, Chemotherapy, and Optional Radiotherapy in Advanced Colorectal Cancer Study Objective: To explore the…
- Trial name
- NCT06521866
- Testing
- Serplulimab, Chemotherapy, SABR
- Where
- 10 sites in China
- Volunteers
- 208 people
- Sponsor
- Fudan University
Lung Cancer
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
- Trial name
- NCT00193453
- Testing
- Gemcitabine, Docetaxel, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- SCRI Development Innovations, LLC
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Neoplasms Malignant
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.
- Trial name
- NCT05155124
- Testing
- Cetuximab + trifluridin tipiracil
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Solid Tumors
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
- Trial name
- NCT06715124
- Testing
- QTX3544, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 237 people
- Sponsor
- Quanta Therapeutics
CRC
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in…
- Trial name
- NCT07204574
- Testing
- HCB101, Bevacizumab, Cetuximab (Erbitux)
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Colorectal Cancer Metastatic, KRAS G12C Mutation
The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer
This is an open-label, multicenter, single-arm Phase II clinical study, divided into subgroups A and B: Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for…
- Trial name
- cruciall (NCT06959589)
- Testing
- IBI351, cetuximab β combined with FOLFIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
- Trial name
- NCT05985954
- Testing
- Cetuximab, Ulixertinib, Encorafenib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck
The goal of this project is to develop and characterise an imaging strategy for biology-guided individualisation of the proton therapy plan to improve patient outcome and quality-of-life.
- Trial name
- ERM-PT-HNSCC (NCT03513042)
- Testing
- Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Leiden University Medical Center
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC
This study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy, safety of SYS6010 compared with monotherapy in participants with HNSCC.
- Trial name
- NCT07758621
- Testing
- SYS6010, Investigator's Choice of monotherapy
- Volunteers
- 340 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Head and Neck Cancer
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: Have benefited from ongoing study treatment as determined by the study doctor in a…
- Trial name
- NCT05226871
- Testing
- Palbociclib, Cetuximab, Fulvestrant
- Where
- 23 sites in United States, China and 5 more
- Volunteers
- 35 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
Registry Multicenter, prospective observational study Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
- Trial name
- NCT03286738
- Testing
- FOLFIRI, target agent
- Where
- South Korea
- Volunteers
- 1,800 people
- Sponsor
- Joong Bae Ahn
Colorectal Liver Metastasis (CRLM)
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes
- Trial name
- NCT06988852
- Testing
- FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), hepatic arterial infusion chemotherapy (HAIC), Bevacizumab
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined.
- Trial name
- NCT05249426
- Testing
- BI 765063, Ezabenlimab, BI 836880
- Where
- 25 sites in United States, France and 9 more
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment
This clinical trial is a Single-Center, Open, Phase I/IIa Clinical Trial conducted to evaluate the safety and anti-tumor activity of SNK01 and GC +/- Cetuximab administered in combination to Locally advanced or Metastatic…
- Trial name
- SNK_ASTER (NCT04872634)
- Testing
- SNK01 (Super Natural Killer Cells 01), GC, Cetuximab
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- NKMAX Co., Ltd.
Non Small Cell Lung Cancer (NSCLC)
Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
This is an open label, phase II study in which cetuximab with concurrent thoracic radiotherapy followed by consolidation chemotherapy with paclitaxel/carboplatin/cetuximab will be administered to subjects with locally advanced…
- Trial name
- NCT00492206
- Testing
- Cetuximab
- Where
- 31 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01816984
- Testing
- PI3K inhibitor BKM120, cetuximab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago